Lab­corp backs Adela’s $48M Se­ries A1 to ad­vance methy­la­tion-based head and neck can­cer test

Adela has raised $48 mil­lion in a Se­ries A1 round backed by new in­vestor and di­ag­nos­tic gi­ant Lab­corp to fund a test for mon­i­tor­ing min­i­mal resid­ual dis­ease (MRD) in head and neck can­cer (HNC).

The round was backed by ex­ist­ing in­vestors, in­clud­ing F-Prime Cap­i­tal, Or­biMed and Deer­field Man­age­ment, bring­ing Adela’s to­tal cap­i­tal raised to date to $108 mil­lion. Lab­corp, which op­er­ates a US net­work of more than 30 pri­ma­ry lab­o­ra­to­ries, al­so pitched in.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER